Clinical Trial Update: Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study of ABBV-552 in mild Alzheimer's disease completed, assessing adverse events, changes in disease activity, and pharmacokinetics in participants a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ABBV-552

Snippet

Sponsor: AbbVie | Conditions: Alzheimer's Disease (AD) | Phase 2 | Status: COMPLETED | Results posted: 2025-10-15